drugset / Trial / NCT03097068
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
Phase 4
Completed
10 enrolled
Vitreo-Retinal Associates, Michigan
Genentech, Inc. · collabMichigan State University · collab
NaSingle-groupOpen-labelBasic science
Summary
The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.
Timeline
- Start
- 2017-04-19
- Primary completion
- 2017-12-06
- Completion
- 2018-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.3 mg | — |